Related Experiment Video

Updated: Jun 23, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of

B Laika1, S Leucht, S Heres

  • 1Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universität München, München, Germany.

The Pharmacogenomics Journal
|May 20, 2009
PubMed

Insights

Intermediate metabolizers (IMs) of cytochrome P450 2D6 (CYP2D6) experience more side effects and prolonged treatment. Identifying IM status can reduce hospitalization costs and improve patient outcomes through CYP2D6 genotyping.

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology
  • Psychiatric Therapeutics

Background:

  • The cytochrome P450 2D6 (CYP2D6) enzyme is crucial for metabolizing approximately 25% of commonly prescribed drugs.
  • CYP2D6 genetic variations significantly influence drug efficacy and safety, particularly in psychiatric treatment.
  • Understanding CYP2D6 metabolizer status is essential for optimizing neuroleptic and antidepressant therapies.

Purpose of the Study:

  • To evaluate the impact of CYP2D6 metabolizer status on therapeutic outcomes in psychiatric inpatients.
  • To determine the relationship between CYP2D6 genotype, drug dosage, side effects, and treatment response.
  • To assess the clinical utility of identifying intermediate metabolizer (IM) status for improved patient management.

Main Methods:

  • A cohort of 365 psychiatric inpatients receiving neuroleptics or antidepressants was studied.
  • Patients' CYP2D6 metabolizer status was assessed.
  • Data on length of hospitalization, response onset, side effects, and Clinical Global Impression scale scores were collected and analyzed.

Main Results:

  • Patients receiving CYP2D6-metabolized drugs experienced prolonged hospitalization and delayed response onset.
  • Intermediate metabolizers (IMs) on higher CYP2D6 drug doses reported significantly more side effects compared to extensive metabolizers and IMs on lower doses.
  • IMs treated with CYP2D6 drugs showed a lower treatment response rate, likely due to increased side effects.

Conclusions:

  • Intermediate metabolizer (IM) status, present in 38% of the study population, is associated with adverse outcomes and reduced treatment efficacy.
  • Identifying IMs can lead to reduced side effects, shorter hospital stays, and lower healthcare costs.
  • CYP2D6 genotyping, including the identification of IMs, is clinically valuable for optimizing drug therapy and improving cost-benefit analyses of pretreatment screening.

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...